Overview: Newborn Screening 4 Panel
Introduction: The Newborn Screening 4 Panel is a diagnostic tool designed to screen for newborn metabolic disorders using whole blood samples. In India, adding galactosemia (GALT deficiency) to TSH, 17-OHP, and G6PD addresses a treatable cause of neonatal jaundice, vomiting, and E. coli sepsis (prevalence ~1 in 30,000â€"60,000). High morbidity from under-screening in rural/low-SES newborns, limited NBS programs, delayed lactose-free formula leading to liver failure or death. Per pediatrics practices aligned with ICMR, NHM, and RBSK guidelines, the test employs PCR for G6PD deficiency, TSH, 17-OHP, and galactosemia over 1-2 days with high accuracy, valuable for expanded NBS in high-risk areas. This diagnostic falls under newborn screening and targets all newborns, addressing accurate detection to guide dietary management and prevent complications. With elevated morbidity due to under-screening, the test supports public health efforts by enabling early intervention and reducing metabolic mortality. Its whole blood-based approach ensures reliable multi-disorder detection.
Other Names: NBS 4 Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.
Historical Milestone: Galactosemia added to NBS pilots in India.
Purpose: The test assesses 4 parameters including G6PD deficiency to guide newborn metabolic screening, detect CH/CAH/G6PD/galactosemia, inform therapy.
Test Parameters: 1. G6PD Deficiency, 2. TSH, 3. 17-OHP, 4. Galactosemia.
Pretest Condition: No fasting required; newborns 48-72 hours old preferred.
Specimen: 3 mL whole blood in 1 EDTA tube (heel prick preferred), transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve DNA/hormone integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for PCR).
Medical History: Parents should provide details on jaundice, feeding issues.
Consent: Written parental informed consent is required, detailing the test's purpose, potential risks of untreated disorders including death, benefits of screening, and minimal discomfort from heel prick.
Procedural Considerations: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or prematurity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal results indicate treatable metabolic disorders, necessitating specialist input.
Specialist Consultation: Pediatric endocrinologists/metabolic specialists should be consulted for management.
Additional Supporting Tests: Serum galactose, enzyme assays for confirmation.
Test Limitations: Basic panel only; comprehensive approach required.
References: Indian Journal of Pediatrics 2024, NBS Studies India 2023.
